Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- DARPP32 PPP1R-1B PPP-1R1B
- Product Overview:
Dopamine and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32) is a member of the protein phosphatase inhibitor 1 family and is encoded by the PPP1R1B gene in humans.{53496} It is primarily expressed in medium spiny neurons of dopamine-innervated brain regions and is localized to the cytoplasm.{53497} DARPP-32 contains multiple phosphorylation sites that allow it to function as a central regulator and integrator of signaling cascades induced by a variety of neurotransmitters, neuropeptides, and psychostimulatory agents. It also contains a protein phosphatase 1 (PP1) binding domain.{53498} DARPP-32 inhibits PP1 when phosphorylated at threonine 34 (Thr34) by PKA and inhibits PKA when phosphorylated at Thr75 by cyclin-dependent kinase 5 (Cdk5). Ppp1r1b-/- mice have decreased amphetamine-induced GABA and dopamine release in the striatum and are less susceptible to catalepsy induced by raclopride (Item No. 17422) compared to wild-type mice.{55186} Increased DARPP-32 protein levels have been identified in breast, prostate, gastric, and colon cancer tumors.{55187} DARPP-32 levels are also increased in postmortem-derived dorsolateral prefrontal cortex from individuals with schizophrenia or bipolar disorder.{55188} Cayman’s DARPP-32 Polyclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes DARPP-32 at ~32 kDa from mouse and rat samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.